Oxford Biomedica (OXB) Competitors

Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Is OXB or GNS more profitable?

Genus has a net margin of 4.96% compared to Oxford Biomedica's net margin of -175.89%. Genus' return on equity of 5.27% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-175.89%	-117.29%	-15.08%
Genus	4.96%	5.27%	3.18%

Does the media prefer OXB or GNS?

In the previous week, Oxford Biomedica had 2 more articles in the media than Genus. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Genus. Oxford Biomedica's average media sentiment score of 1.29 beat Genus' score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Biomedica	Positive
Genus	Neutral

Which has preferable earnings and valuation, OXB or GNS?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£89.54M	3.70	-£157.49M	-£1.63	-203.07
Genus	£673.10M	1.77	£33.40M	£0.49	3,677.55

Do insiders & institutionals have more ownership in OXB or GNS?

57.9% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 78.5% of Genus shares are owned by institutional investors. 16.2% of Oxford Biomedica shares are owned by company insiders. Comparatively, 0.7% of Genus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more risk & volatility, OXB or GNS?

Oxford Biomedica has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Genus has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Do analysts rate OXB or GNS?

Oxford Biomedica presently has a consensus target price of GBX 431.25, indicating a potential upside of 30.29%. Given Oxford Biomedica's higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Genus	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the MarketBeat Community prefer OXB or GNS?

Oxford Biomedica received 9 more outperform votes than Genus when rated by MarketBeat users. However, 70.56% of users gave Genus an outperform vote while only 66.85% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Oxford Biomedica	Outperform Votes 359 66.85%	Underperform Votes 178 33.15%
Genus	Outperform Votes 350 70.56%	Underperform Votes 146 29.44%

Summary

Genus beats Oxford Biomedica on 9 of the 17 factors compared between the two stocks.